US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 2.120
- +0.090+4.43%
Close Sep 13 16:00 ET
- 2.140
- +0.020+0.94%
Post 19:33 ET
191.57MMarket Cap-1606P/E (TTM)
2.135High2.064Low718.63KVolume2.090Open2.030Pre Close1.51MTurnover0.88%Turnover RatioLossP/E (Static)90.36MShares8.33052wk High0.62P/B172.69MFloat Cap1.50052wk Low--Dividend TTM81.46MShs Float32.645Historical High--Div YieldTTM3.50%Amplitude1.500Historical Low2.107Avg Price1Lot Size
Caribou Biosciences Stock Forum
Sign in to post a comment
$Caribou Biosciences (CRBU.US)$
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
3
5
$Caribou Biosciences (CRBU.US)$ Reuters· just
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
2
$Caribou Biosciences (CRBU.US)$
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
1
$Caribou Biosciences (CRBU.US)$ Got a inverted hammer on the daily! Its wick actually broke above the downtrend continuation wedge! Its Really OS RSI 7 = 14.58! RSI 14 = 24.96! MACD Looks as if its fixing to GC? So lets just see how this turns out? Just thinking outloud![]()
3
3
$Caribou Biosciences (CRBU.US)$ Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
2
Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.
Caribou Biosciences' revenue growth is promising but rising cash burn rate could concern investors. Raising more capital may result in shareholder dilution, making the situation risky.
$Caribou Biosciences (CRBU.US)$ Caribou Biosciences (CRBU) said late Tuesday it has reached alignment with the US Food and Drug Administration with respect to the trial design of a planned phase 3 study of CB-010 for the treatment of patients with second-line relapsed or refractory large B cell lymphoma.
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
1
$Caribou Biosciences (CRBU.US)$ Bring on the volume! Another PR just hitting most outlets now! Hehehe![]()
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Rockhoundj : Whaddya think about FRGT$Freight Technologies (FRGT.US)$ ?
FattyChick OP Rockhoundj : From the last RS earlier this year, the next RS coming soon
FattyChick OP Rockhoundj : If you really want to get a position, entry 0.108 - 0.11.
TP 0.136.
Rockhoundj FattyChick OP : I’m holding just under .13
With a tight stop loss
Jenna Ragan : these look nice![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")